We use own cookies and thirds to offer you better service More information Accept

The strategic core business of Invent Farma Group is the Central Nervous System

The Invent Farma Group is strategically focused on the development, manufacture and marketing of drugs indicated for the treatment of the Central Nervous System (CNS) disorders.

Thanks to the outstanding development capability of the Group we are able to offer to our clients a wide range of products for this particular therapeutic area through our subsidiaries:

  • Laboratorios Lesvi: Highly flexible approach along with a broad experience in the development and manufacturing of finished dosage forms allowing us to become the reliable partners for both large national and international third-party laboratories.
    FDFs - Lesvi Product List
  • Qualigen: Expertise in the Central Nervous System field allowing us to reach with differentiated drugs both the retail pharmacists and the medical specialists mainly on the Psychiatry, Neurology and Pain branches in the domestic market in Spain.
  • Product list by indication
  • Pharmacists:
    Generics Vademecum
  • Medical specialists:
    CNS Line Vademecum

The strategic combination of companies within the NuPharm Group, of which Invent Farma Group is the Spanish outlet, has as a goal becoming the Pan-European leader in pharmaceutical products for the treatment of disorders of the Central Nervous System.

Our sister companies in the NuPharm Group are:

  • neuraxpharm Arzneimittel GmbH: A Düsseldorf-based leader in generic pharmaceutical products for the treatment of disorders of the Central Nervous System (CNS). The company, which has a portfolio of 100 predominantly differentiated products to serve the needs of CNS patients, is a trusted brand for neurologists, psychiatrists, pharmacists and patients for over three decades.
  • FB Health: An Italy-based specialty pharma company focused on the research, development and commercialization of innovative nutraceuticals and pharmaceuticals in Italy for the prevention and treatment of pathologies affecting elderly people, with a particular focus towards Neurology, Geriatrics and Psychiatry.

The integration of all the companies within NuPharm Group will allow operational synergies in strategic aspects such as procurement, R&D, manufacturing, cross-licensing and geographical expansion.